Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

Nature Communications

Volumn 8, Issue , 2017, Pages

  Inoue Yamauchi, Akane ^a,d   Jeng, Paul S ^a   Kim, Kwanghee ^a   Chen, Hui Chen ^a   Han, Song ^a   Ganesan, Yogesh Tengarai ^a   Ishizawa, Kota ^a   Jebiwott, Sylvia ^a   Dong, Yiyu ^a   Pietanza, Maria C ^a,b   Hellmann, Matthew D ^a,b   Kris, Mark G ^a,b   Hsieh, James J ^c   Cheng, Emily H ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c USA   (United States)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLIN DEPENDENT KINASE 9; DINACICLIB; DOXORUBICIN; NAVITOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; VENETOCLAX; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL2 PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; MCL1 PROTEIN, HUMAN; PROTEIN BCL X; PROTEIN KINASE INHIBITOR; PYRIDINIUM DERIVATIVE; SULFONAMIDE;

ACTIVATION ENERGY; APOPTOSIS; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; INHIBITION; INHIBITOR; MOLECULAR ANALYSIS; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; MITOCHONDRION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SMALL CELL LUNG CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; DRUG RESISTANCE; HUMAN; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 9; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINIUM COMPOUNDS; SMALL CELL LUNG CARCINOMA; SULFONAMIDES;

EID: 85024492846     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms16078     Document Type: Article

References (50)

1. Czabotar, P. E., Lessene, G., Strasser, A., Adams, J. M. Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49-63 (2014).
2. Cheng, E. H. et al. BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX-A nd BAK-mediated mitochondrial apoptosis. Mol. Cell 8, 705-711 (2001).
3. Kim, H. et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8, 1348-1358 (2006).
4. Kim, H. et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell 36, 487-499 (2009).
5. Ren, D. et al. BID, BIM, and PUMA are essential for activation of the BAX-A nd BAK-dependent cell death program. Science 330, 1390-1393 (2010).
6. Chen, H. C. et al. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat. Cell Biol. 17, 1270-1281 (2015).
7. Dewson, G. et al. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Mol. Cell 30, 369-380 (2008).
8. Willis, S. N. et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856-859 (2007).
9. Korsmeyer, S. J. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80, 879-886 (1992).
10. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
11. Tse, C. et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008).
12. Davids, M. S., Letai, A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J. Clin. Oncol. 30, 3127-3135 (2012).
13. Walensky, L. D. From mitochondrial biology to magic bullet: Navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J. Clin. Oncol. 30, 554-557 (2012).
14. Anderson, M. A., Huang, D., Roberts, A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin. Hematol. 51, 219-227 (2014).
15. Gandhi, L. et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909-916 (2011).
16. Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163-3169 (2012).
17. Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208 (2013).
18. Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311-322 (2016).
19. Leverson, J. D. et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra240 (2015).
20. Semenova, E. A., Nagel, R., Berns, A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 29, 1447-1462 (2015).
21. William, Jr W. N., Glisson, B. S. Novel strategies for the treatment of small-cell lung carcinoma. Nat. Rev. Clin. Oncol. 8, 611-619 (2011).
22. George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47-53 (2015).
23. Peifer, M. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104-1110 (2012).
24. Shoemaker, A. R. et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res. 14, 3268-3277 (2008).
25. Faber, A. C. et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc. Natl Acad. Sci. USA 112, E1288-E1296 (2015).
26. Wei, G. et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 21, 547-562 (2012).
27. Brasca, M. G. et al. Optimization of 6, 6-dimethyl pyrrolo[3, 4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg. Med. Chem. 18, 1844-1853 (2010).
28. Wang, S., Fischer, P. M. Cyclin-dependent kinase 9: A key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol. Sci. 29, 302-313 (2008).
29. Hsin, J. P., Manley, J. L. The RNA polymerase II CTD coordinates transcription and RNA processing. Genes Dev. 26, 2119-2137 (2012).
30. MacCallum, D. E. et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65, 5399-5407 (2005).
31. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770-1783 (2006).
32. Kumar, S. K. et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 125, 443-448 (2015).
33. Gardner, E. E. et al. Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res. 74, 2846-2856 (2014).
34. Cheng, E. H., Sheiko, T. V., Fisher, J. K., Craigen, W. J., Korsmeyer, S. J. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 301, 513-517 (2003).
35. Willis, S. N. et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19, 1294-1305 (2005).
36. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
37. Huang, C. H. et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 28, 1800-1814 (2014).
38. Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013).
39. Lockwood, W. W., Zejnullahu, K., Bradner, J. E., Varmus, H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc. Natl Acad. Sci. USA 109, 19408-19413 (2012).
40. Hanahan, D., Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
41. Lowe, S. W., Cepero, E., Evan, G. Intrinsic tumour suppression. Nature 432, 307-315 (2004).
42. Hershko, T., Ginsberg, D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 279, 8627-8634 (2004).
43. Chen, S., Dai, Y., Pei, X. Y., Grant, S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: Evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol. Cell Biol. 29, 6149-6169 (2009).
44. Bean, G. R. et al. PUMA and BIM are required for oncogene inactivationinduced apoptosis. Sci. Signal. 6, ra20 (2013).
45. Corcoran, R. B. et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23, 121-128 (2013).
46. Christensen, C. L. et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26, 909-922 (2014).
47. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
48. Morales, A. A. et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 118, 1329-1339 (2011).
49. Dai, H. et al. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes Dev. 29, 2140-2152 (2015).
50. Deng, J. et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12, 171-185 (2007).